Recital 18, Regulation (EU) 2024/3169

In forcesince 18 Dec 2024

In accordance with Article 5(1), point (a), of Regulation (EU) 2018/1725 of the European Parliament and of the Council [Regulation (EU) 2018/1725 of the European Parliament and of the Council of 23 October 2018 on the protection of natural persons with regard to the processing of personal data by the Union institutions, bodies, offices and agencies and on the free movement of such data, and repealing Regulation (EC) No 45/2001 and Decision No 1247/2002/EC (OJ L 295, 21.11.2018, p. 39 ELI: http://data.europa.eu/eli/reg/2018/1725/oj).], it is necessary to lay down the rules for processing of personal data for the purposes of conducting joint scientific consultations on medicinal products. In particular, it is necessary to specify the personal data that may be processed, namely certain personal data relating to the individual experts involved in joint scientific consultations on medicinal products and certain personal data relating to the representatives appointed to the Coordination Group and the JSC Subgroup, the representatives of health technology developers and the representatives of the members of the stakeholder network. Where joint scientific consultations on medicinal products are conducted in parallel with the scientific advice, the Commission should receive from the European Medicines Agency the list of participants involved in the scientific advice that are invited to the meeting with the health technology developer.